Pharmidex partners in European Commission H2020 award
May 21, 2017

Pharmidex joins Horizon 2020 EU project to work on radioactive contamination

Pharmidex partners in European Commission H2020 award

This project aims to stimulate intersectoral and international collaboration within Europe and with an ICPC country, Kazakhstan, in the area of novel nanoporous and nanostructured adsorbents for the treatment of very serious health conditions associated with acute and chronic exposure to external radiation and uptake of heavy metals and radiation as a consequence of accidental, occupational or deliberate activities and events.


This can dramatically lower the quality of life of the people affected and at present the treatment available is costly and inefficient. Radioactive contamination is a particularly serious problem in two of the countries participating in this project, namely, Ukraine and Kazakhstan, on large territories of the Chernobyl zone and around Semipalatinsk nuclear test site, respectively.


A large number of people are affected by living in the areas with elevated level of radioactivity with uncertain long-term consequences to their health and the health of future generations.


The expected impact of the project results is development of efficient and cost-effective methods of protection of first responders, population and cancer patients treated with radiotherapy from elevated doses of external and incorporated radiation and for occupational health protection of personnel working and the population living in areas contaminated with heavy metals.


Please find more information on the following web page: http://cordis.europa.eu/project/rcn/207057_en.html

March 24, 2026
We are pleased to share our latest publication: “Magnetic field-induced drug delivery from magnetic microporous nanocomposites through magnetic nanoparticles heating or motion” , published in the journal Materials & Design . This work explores innovative approaches to magnetically triggered drug delivery, leveraging the unique properties of magnetic nanoparticles to enable controlled release through heating and motion mechanisms. These advances have the potential to open new avenues in targeted therapies and precision medicine. We would like to sincerely thank our collaborators for their valuable contributions to this research: -CRCT Université de Toulouse Inserm U1037 CNR -Laboratoire de Physique et Chimie des Nano-Objets (LPCNO) CNRS-UPS-INSA -Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) We are proud to contribute to cutting-edge research at the interface of nanotechnology and drug delivery and we look forward to continuing collaborations that drive innovation in drug discovery and development. 🔗 Read the full article: https://www.sciencedirect.com/science/article/pii/S0264127526003084?via%3Dihub
March 16, 2026
Pharmidex is proud to be the Networking Sponsor at the Immuno-Oncology & Biomarker Summit in London. Over the next two days, the event provides an opportunity to discuss the latest advances in immuno-oncology, biomarker discovery, and precision medicine. If you’re attending, come and say hello to Ash Alavijeh to connect and explore opportunities to collaborate.
March 13, 2026
We’re excited to announce that Janette Dalay Robertson , Business Development Manager at Pharmidex , will be attending and exhibiting at the 10th RSC-BMCS Symposium on Mastering Medicinal Chemistry on Friday 13 March 2026 at Burlington House, London. Pharmidex is also proud to be sponsoring this fantastic event, which brings together leaders and innovators from across the medicinal chemistry community. If you’re attending, make sure to stop by and speak with Janette at the Pharmidex stand. She will be delighted to connect, discuss your research, and explore how Pharmidex can support your drug discovery and development programmes. 🤝 We look forward to meeting fellow scientists, collaborators, and partners at this exciting meeting.
More Posts